Premium
Siponimod for treating secondary progressive multiple sclerosis
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1882
Subject(s) - medicine , multiple sclerosis , physical medicine and rehabilitation , immunology
Siponimod (Mayzent) is a sphingosine‐1‐phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis. This article discusses its properties, place in therapy, efficacy and adverse effects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom